2019
IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA
Sun M, Orpilla J, Contreras E, Treger J, Molaie D, Tsang J, Antonios J, Wang A, Liau L, Prins R, Everson R. IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA. Neuro-Oncology 2019, 21: vi129-vi130. PMCID: PMC6847786, DOI: 10.1093/neuonc/noz175.542.Peer-Reviewed Original ResearchTCR-transduced T cellsNY-ESO-1 expressionNY-ESO-1Targeting NY-ESO-1Systemic adoptive transferAdoptive transferT cellsNY-ESO-1 mRNA expressionT cells in vitroSurvival benefit in vivoAdoptive transfer immunotherapyIncreased overall survivalIn vitro cytolysisMeningiomas in vitroHigher-grade meningiomasIn vivoReal-time cell analyzer systemAugment immunotherapyBenefit in vivoTumor cytolysisCT antigensImmunotherapeutic strategiesNSG miceOverall survivalImmunotherapy development
2018
ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION
Antonios J, Everson R, Soto H, Khattab S, Bethel J, Sun M, Mochizuki A, Lee A, Odesa S, Billingslea-Yoon E, Moughon D, Wang A, Cloughesy T, Prins R, Liau L. ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION. Neuro-Oncology 2018, 20: vi10-vi10. PMCID: PMC6216157, DOI: 10.1093/neuonc/noy148.034.Peer-Reviewed Original ResearchToll-like receptorsMedian survivalDendritic cellsDC vaccinesGrade III or IV gliomaTumor lysate-pulsed DCGlioblastoma multiformePoly ICLCAutologous tumor lysateDC vaccine treatmentLysate-pulsed DCMGMT methylated tumorsMGMT unmethylated tumorsTLR-7 agonistPeripheral blood mononuclear cellsGrade III tumorsTLR-3 agonistIncreased overall survivalGrade IV tumorsBlood mononuclear cellsModulate immune responsesIII tumorsIV tumorsMethylated tumorsOverall survival